Zydus Lifesciences receives USFDA approval for Estradiol Transdermal System

8 Dec 2022 , 01:34 AM

Zydus Lifesciences has received final approval from the United States Food and Drug Administration USFDA to market Estradiol Transdermal System USP 0025 mgday 00375 mgday 005 mgday 0075 mgday and 01 mgday USRLD Vivelle-Dot Transdermal System Estradiol Transdermal System is indicated to treat moderate to severe symptoms of menopause which includes feelings of warmth in the face neck and chest or sudden strong feelings of heat hot flushes and vaginal dryness in women The drug will be manufactured at the groups formulation manufacturing facility at Moraiya Ahmedabad India